The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II clinical study of radium-223 chloride (BAY 88-8223) in Japanese patients with symptomatic castration-resistant prostate cancer (CRPC) with bone metastases.
 
Hiroji Uemura
Honoraria - Astellas Pharma; AstraZeneca Japan; Bayer Yakuhin; Daiichi Sankyo; GlaxoSmithKline K.K.; Janssen; Kissei Pharmaceutical; Sanofi
Consulting or Advisory Role - Bayer Yakuhin; Daiichi Sankyo; Janssen
Speakers' Bureau - Astellas Pharma; AstraZeneca Japan; Bayer Yakuhin; Daiichi Sankyo; Janssen; Kissei Pharmaceutical; Sanofi
Research Funding - Astellas Pharma (Inst); Bayer Yakuhin (Inst)
 
Satoshi Nagamori
Honoraria - Daiichi Sankyo; Kyowa Hakko Kirin
Speakers' Bureau - Daiichi Sankyo; Kyowa Hakko Kirin
Research Funding - Bayer Yakuhin (Inst); Takeda (Inst)
 
Yoshiaki Wakumoto
Honoraria - ASKA Pharmaceutical; Astellas Pharma; AstraZeneca Japan; Olympus
Speakers' Bureau - ASKA Pharmaceutical; Astellas Pharma; AstraZeneca Japan; Olympus
Research Funding - Bayer Yakuhin (Inst)
 
Hirotsugu Uemura
Honoraria - Astellas Pharma; AstraZeneca Japan; Bayer Yakuhin; GlaxoSmithKline K.K.; Janssen; Novartis; Ono Pharmaceutical; Pfizer; Sanofi; Takeda
Consulting or Advisory Role - Bayer Yakuhin
Speakers' Bureau - Astellas Pharma; AstraZeneca Japan; Bayer Yakuhin; GlaxoSmithKline K.K.; Janssen; Novartis; Ono Pharmaceutical; Pfizer; Sanofi; Takeda
Research Funding - AstraZeneca Japan (Inst); Pfizer (Inst); Sanofi (Inst)
 
Go Kimura
Honoraria - Janssen; Ono Pharmaceutical
Speakers' Bureau - Astellas Pharma; Bayer Yakuhin; GlaxoSmithKline K.K.; Pfizer; Sanofi; Takeda
Research Funding - Astellas Pharma (Inst); Bayer Yakuhin (Inst); Chugai Pharma (Inst); GlaxoSmithKline K.K. (Inst); Ono Pharmaceutical (Inst); Takeda (Inst)
 
Akira Yokomizo
Honoraria - Astellas Pharma; AstraZeneca Japan
Consulting or Advisory Role - Bayer Yakuhin
 
Hiroaki Kikukawa
Honoraria - Astellas Pharma; AstraZeneca Japan; Nippon Kayaku; Takeda
Speakers' Bureau - Astellas Pharma; Astellas Pharma; AstraZeneca Japan; Takeda
 
Atsushi Mizokami
No Relationships to Disclose
 
Takeo Kosaka
Honoraria - Astellas Pharma; Sanofi
Speakers' Bureau - AstraZeneca Japan; Sanofi
Research Funding - Astellas Pharma (Inst); AstraZeneca Japan (Inst); Sanofi (Inst); Takeda (Inst)
 
Naoya Masumori
Honoraria - Asahi Kasei; Astellas Pharma; AstraZeneca Japan; Bayer Yakuhin; GlaxoSmithKline K.K.; Janssen; Nippon Shinyaku; Pfizer; Sanofi; Takeda
Consulting or Advisory Role - Bayer Yakuhin; GlaxoSmithKline K.K.
Speakers' Bureau - Asahi Kasei; Astellas Pharma; AstraZeneca Japan; Bayer Yakuhin; GlaxoSmithKline K.K.; Janssen; Nippon Shinyaku; Pfizer; Sanofi; Takeda
 
Yoshihide Kawasaki
No Relationships to Disclose
 
Junji Yonese
No Relationships to Disclose
 
Yasutomo Nasu
Stock and Other Ownership Interests - Momotaro Gene Inc.
Honoraria - Astellas Pharma; AstraZeneca Japan
Speakers' Bureau - Astellas Pharma; AstraZeneca Japan
Patents, Royalties, Other Intellectual Property - Momotaro Gene Inc.
 
Satoshi Fukasawa
Research Funding - Astellas Pharma (Inst); Bayer Yakuhin (Inst); GreenPeptide (Inst); Janssen (Inst); Lilly (Inst); Merck KGaA (Inst); Nihon Medi-Physics (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Proacta (Inst)
 
Takayuki Sugiyama
Honoraria - GlaxoSmithKline K.K.
Research Funding - Bayer Yakuhin (Inst); GreenPeptide (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bayer Yakuhin; GreenPeptide
 
Motohide Uemura
Honoraria - Astellas Pharma; AstraZeneca Japan; Janssen; Pfizer
Speakers' Bureau - Astellas Pharma; AstraZeneca Japan; Pfizer; Sanofi; Takeda
Research Funding - Bayer Yakuhin (Inst); Chugai Pharma (Inst); Lilly (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - Osaka university
 
Iku Yamaguchi
Employment - Bayer Yakuhin
Stock and Other Ownership Interests - Bayer
Travel, Accommodations, Expenses - Bayer Yakuhin
 
Hirokazu Tsutsui
Employment - Bayer Yakuhin
Travel, Accommodations, Expenses - Bayer Yakuhin
 
Eisuke Matsunaga
Employment - Bayer Yakuhin
Stock and Other Ownership Interests - Bayer
Travel, Accommodations, Expenses - Bayer Yakuhin
 
Nobuaki Matsubara
Honoraria - AstraZeneca Japan; Janssen; Sanofi
Consulting or Advisory Role - AstraZeneca Japan; Janssen
Speakers' Bureau - AstraZeneca Japan; Janssen; Sanofi
Research Funding - AstraZeneca Japan (Inst); Bayer Yakuhin (Inst); Janssen (Inst); Sanofi (Inst)